What Icon’s $300M Microsoft Bet Means for the Sites Running Their Trials
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...
Icon's enterprise-wide Microsoft Copilot deployment and $300M AI investment will reshape how CRAs monitor, query, and escalate — here's...
The Lancet correspondence on the MASAI trial exposes a core evidentiary gap: AI mammography's performance gains rest on intermediate...
Icon's Microsoft-Copilot partnership scales its Orbis AI platform enterprise-wide. For sites and sponsors mid-trial, the operational cost question starts...
MIRA beat physicians on diagnostic accuracy. AMIE matched them across 100 cases. Now comes the real test: whether regulated...
A Nature Medicine study finds GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools on...
Eli Lilly invested in Abridge's AI recruitment tool — but the real question is whether sites can operationalize patient...
ASCO and Ryght AI are using algorithms to select CDK4/6 inhibitor trial sites. Here's what ops teams need to...
ASCO and Ryght AI are using machine learning to select breast cancer trial sites. Here's what that means for...
At the 2026 Veeva R&D and Quality Summit in Copenhagen, Veeva Systems announced three major AI capabilities: Vault AI,...
Phesi finds fewer than 1 in 3 trial protocols connect to real patient data — meaning flawed assumptions reach...